Neumora Therapeutics Inc

Trading Arrangements

The following table describes, for the three months ended June 30, 2024, each trading arrangement for the purchase or sale of Company securities adopted, modified or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a Rule 10b5-1 trading arrangement, or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):

*Intended to satisfy the affirmative defense of Rule 10b5-1(c)

**Not intended to satisfy the affirmative defense of Rule 10b5-1(c)

(1) Changed the timing and price limits of sales under the trading arrangement originally adopted on April 18, 2024.

(2) This 10b5-1 trading arrangement is intended to qualify as an “eligible sell-to-cover transaction” (as described in Rule 10b5-1(c)(1)(ii)(D)(3) under the Exchange Act). This sell-to-cover arrangement applies to restricted stock units (“RSUs”). This arrangement provides for the automatic sale of shares of common stock that would otherwise be issuable on each vesting date of a covered RSU in an amount necessary to satisfy the applicable withholding obligation, with the proceeds of the sale delivered to us in satisfaction of the applicable withholding obligation. The number of shares of common stock that will be sold under this arrangement is not currently determinable as the number will vary based on the extent to which vesting conditions are satisfied, the market price of our common stock at the time of settlement and the potential future grant of additional RSUs subject to this arrangement.